-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32

Benzinga·06/01/2026 10:28:09
Listen to the news
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $32.